Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | SERPINE1 | P05121 | 5/20 | 0.50 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | HMGCR | P04035 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | TST | Q16762 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27979279 | 1.00 | TDP1 (0.57) | TDP1SERPINE1TMPRSS2USP2PDE5A | |
| SCHEMBL28455116 | 0.87 | TMPRSS2 (0.57) | TDP1SERPINE1TMPRSS2USP2PDE5A | |
| SCHEMBL28460100 | 0.87 | TMPRSS2 (0.57) | TDP1SERPINE1TMPRSS2USP2PDE5A | |
| SCHEMBL20530397 | 0.85 | TDP1 (0.55) | TDP1SERPINE1TMPRSS2USP2PDE5A | |
| SCHEMBL10379318 | 0.85 | TDP1 (0.63) | TDP1SERPINE1TMPRSS2USP2PDE5A | |
| SCHEMBL30083919 | 0.85 | TDP1 (0.63) | TDP1SERPINE1TMPRSS2USP2PDE5A | |
| SCHEMBL13456976 | 0.85 | TDP1 (0.63) | TDP1SERPINE1TMPRSS2USP2PDE5A | |
| SCHEMBL13430932 | 0.85 | TDP1 (0.63) | TDP1SERPINE1TMPRSS2USP2PDE5A | |
| SCHEMBL17274609 | 0.84 | TDP1 (0.68) | TDP1SERPINE1TMPRSS2USP2PDE5A | |
| SCHEMBL19145553 | 0.84 | TDP1 (0.68) | TDP1SERPINE1TMPRSS2USP2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014362-A1 | ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE | CHATTERJEE SUBROTO (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170014362-A1 | ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE | CHATTERJEE SUBROTO (US) | 2017-01-19 | — | — | US | disclosed |
| US-9376369-B2 | Anti-cholesterolemic compounds and methods of use | CHATTERJEE SUBROTO (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376369-B2 | Anti-cholesterolemic compounds and methods of use | CHATTERJEE SUBROTO (US) | 2016-06-28 | — | — | US | disclosed |
| US-20140031304-A1 | ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE | CHATTERJEE SUBROTO (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031304-A1 | ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE | CHATTERJEE SUBROTO (US) | 2014-01-30 | — | — | US | disclosed |
| US-8492351-B2 | Anti-cholesterolemic compounds and methods of use | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-07-23 | — | — | US | disclosed |
| US-8492351-B2 | Anti-cholesterolemic compounds and methods of use | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-07-23 | — | — | US | disclosed |
| US-20100063153-A1 | ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100063153-A1 | ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063153-A1 | ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE | CETP, NPC1L1, HMGCR | TDP1 2712/4885SERPINE1 1091/4885TMPRSS2 1721/4885 |
| US-20140031304-A1 | ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE | CETP, NPC1L1, HMGCR | TDP1 2712/4885SERPINE1 1091/4885TMPRSS2 1721/4885 |
| US-20170014362-A1 | ANTI-CHOLESTEROLEMIC COMPOUNDS AND METHODS OF USE | CETP, NPC1L1, HMGCR | TDP1 2712/4885SERPINE1 1091/4885TMPRSS2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.